Eli Lilly and Company and Incyte Corporation are jointly developing baricitinib, an oral JAK1
and 2 inhibitor, under a worldwide license and collaboration agreement in which Lilly has the licensing rights.
Late-breaking data on investigational medicine ABT-494, a selective JAK1
inhibitor, to be presented
July 30 (SeeNews) - Belgium-based biotechnology firm Galapagos (AMS:GLPG) said Wednesday the selective JAK1
GSK2586184 is the second selective JAK1
molecule discovered by Galapagos to enter Phase 2 studies.
Lilly and Incyte's Oral JAK1
and JAK2 Inhibitor, Baricitinib, Showed Positive
Jakafi([R]) (ruxolitinib) - a JAK1
and JAK2 Inhibitor
About Baricitinib Baricitinib is a once-daily, oral, selective JAK1
and JAK2 inhibitor.
April 28 (SeeNews) - Belgian biotechnology firm Galapagos (AMS:GLPG) said Monday its selective JAK1
inhibitor filgotinib had met key efficacy
/ JAK2 inhibitor - This molecule is being developed in
JAK2 is a member of the Janus family of mammalian tyrosine kinases, which is comprised of four cytoplasmic tyrosine kinases : JAK1
, JAK2, JAK3 and TYK2 (Imada and Leonard, 2000; Zhu et al.
25, 2015 /PRNewswire/ -- AbbVie (NYSE:ABBV), a global biopharmaceutical company, today announced results from two Phase 2 clinical trials evaluating its investigational selective JAK1
inhibitor, ABT-494, in patients with inadequate response to either methotrexate or TNF inhibitors.
25, 2015 /PRNewswire/ -- AbbVie (NYSE:ABBV), a global biopharmaceutical company, today announced that it will advance ABT-494, its internally developed investigational selective JAK1
inhibitor, to Phase 3 studies in rheumatoid arthritis.